A detailed history of Federated Hermes, Inc. transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Federated Hermes, Inc. holds 5,608,200 shares of DVAX stock, worth $71.3 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,608,200
Previous 7,146,769 21.53%
Holding current value
$71.3 Million
Previous $80.3 Million 22.16%
% of portfolio
0.14%
Previous 0.19%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.05 - $11.61 $15.5 Million - $17.9 Million
-1,538,569 Reduced 21.53%
5,608,200 $62.5 Million
Q2 2024

Aug 08, 2024

SELL
$10.73 - $12.58 $9.03 Million - $10.6 Million
-842,005 Reduced 10.54%
7,146,769 $80.3 Million
Q1 2024

May 14, 2024

SELL
$11.7 - $14.98 $39.5 Million - $50.6 Million
-3,375,892 Reduced 29.71%
7,988,774 $99.1 Million
Q4 2023

Jan 31, 2024

SELL
$13.09 - $14.98 $16.5 Million - $18.9 Million
-1,264,059 Reduced 10.01%
11,364,666 $159 Million
Q3 2023

Nov 13, 2023

SELL
$12.64 - $14.99 $336,704 - $399,303
-26,638 Reduced 0.21%
12,628,725 $187 Million
Q1 2023

May 08, 2023

BUY
$9.44 - $11.88 $141,600 - $178,200
15,000 Added 0.12%
12,655,363 $124 Million
Q4 2022

Feb 13, 2023

BUY
$10.27 - $13.29 $256,750 - $332,250
25,000 Added 0.2%
12,640,363 $134 Million
Q3 2022

Nov 14, 2022

SELL
$9.93 - $17.44 $33.8 Million - $59.4 Million
-3,407,368 Reduced 21.27%
12,615,363 $132 Million
Q2 2022

Aug 15, 2022

SELL
$7.45 - $12.83 $3.84 Million - $6.61 Million
-515,107 Reduced 3.11%
16,022,731 $202 Million
Q1 2022

May 13, 2022

BUY
$9.75 - $14.44 $3.22 Million - $4.77 Million
330,000 Added 2.04%
16,537,838 $179 Million
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $11.5 Million - $18.3 Million
874,438 Added 5.7%
16,207,838 $228 Million
Q3 2021

Nov 15, 2021

BUY
$9.16 - $19.83 $9.98 Million - $21.6 Million
1,089,600 Added 7.65%
15,333,400 $295 Million
Q2 2021

Aug 16, 2021

BUY
$7.25 - $10.99 $11.9 Million - $18 Million
1,639,077 Added 13.0%
14,243,800 $140 Million
Q1 2021

May 13, 2021

BUY
$4.57 - $11.18 $3.01 Million - $7.36 Million
657,923 Added 5.51%
12,604,723 $124 Million
Q4 2020

Feb 12, 2021

BUY
$3.73 - $5.6 $3.73 Million - $5.6 Million
1,000,000 Added 9.14%
11,946,800 $53.2 Million
Q3 2020

Nov 12, 2020

SELL
$4.32 - $11.7 $950,400 - $2.57 Million
-220,000 Reduced 1.97%
10,946,800 $47.3 Million
Q2 2020

Aug 13, 2020

BUY
$2.94 - $9.1 $4.12 Million - $12.7 Million
1,400,000 Added 14.33%
11,166,800 $99.1 Million
Q1 2020

May 13, 2020

BUY
$2.27 - $6.2 $1.18 Million - $3.22 Million
520,000 Added 5.62%
9,766,800 $34.5 Million
Q4 2019

Feb 14, 2020

BUY
$3.46 - $6.93 $1.71 Million - $3.43 Million
495,350 Added 5.66%
9,246,800 $52.9 Million
Q3 2019

Nov 14, 2019

BUY
$2.69 - $4.85 $10.5 Million - $19 Million
3,910,750 Added 80.79%
8,751,450 $31.3 Million
Q2 2019

Aug 14, 2019

BUY
$3.65 - $7.89 $3.75 Million - $8.11 Million
1,027,300 Added 26.94%
4,840,700 $19.3 Million
Q1 2019

May 10, 2019

BUY
$7.08 - $12.09 $1.07 Million - $1.84 Million
151,800 Added 4.15%
3,813,400 $27.9 Million
Q4 2018

Feb 13, 2019

BUY
$8.14 - $13.28 $16.8 Million - $27.4 Million
2,062,348 Added 128.96%
3,661,600 $33.5 Million
Q3 2018

Nov 13, 2018

SELL
$11.85 - $16.0 $693,497 - $936,368
-58,523 Reduced 3.53%
1,599,252 $19.8 Million
Q2 2018

Aug 10, 2018

SELL
$15.15 - $20.75 $11.6 Million - $15.9 Million
-764,654 Reduced 31.57%
1,657,775 $25.3 Million
Q1 2018

May 09, 2018

SELL
$14.65 - $19.9 $645,171 - $876,376
-44,039 Reduced 1.79%
2,422,429 $48.1 Million
Q4 2017

Feb 14, 2018

SELL
$17.3 - $24.08 $1.75 Million - $2.44 Million
-101,292 Reduced 3.94%
2,466,468 $0
Q3 2017

Nov 13, 2017

BUY
$15.2 - $21.5 $39 Million - $55.2 Million
2,567,760
2,567,760 $55.2 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.61B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.